Back to News & Events

BARDA Mask Innovation Challenge Awards Ceremony

June 24, 2021 – 12:30-1:30 ET
Online

The Biomedical Advanced Research & Development Authority’s Division of Research, Innovation, & Ventures (BARDA DRIVe), in partnership with the National Institute for Occupational Safety and Health (NIOSH), is proud to present the Awards Ceremony for the “Mask Innovation Challenge: Building Tomorrow’s Mask.”

This event will celebrate the 10 Phase 1 finalist teams. They’ve all been working tirelessly to answer the PPE challenge of the pandemic era: Re-imagining and creating the mask of the future.

Learn more and register: https://www.eventbrite.com/e/barda-mask-innovation-challenge-awards-ceremony-tickets-157715949651

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3908 [post_author] => 1 [post_date] => 2022-06-13 13:15:29 [post_date_gmt] => 2022-06-13 13:15:29 [post_content] =>


The Center for Biotechnology will be co hosting a series of 6- 90 minute panel discussions with industry and government partners, focused on providing guidance and insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA).

Each event will have its own specific focus, while contributing to a sequential flow for the series. Experts with specific backgrounds will provide an overview of key resources available to innovators to help fund and advance their solution from early through late stages of development, as well as provide guidance on how to navigate the funding opportunities within BARDA and BARDA DRIVe.

Session dates: June 14, 17, 21, 24, 28 and July 1st. 12:00om - 1:#0pm EST. Learn more and register: 
https://lnkd.in/gYnTAgDh

This program is a collaborative effort between incubators and accelerators who are partnered with them through their Division of Research, Innovation & Ventures (DRIVe).

[post_title] => Bench to BARDA Start Up Series (Virtual) [post_excerpt] => A virtual series providing insight into how innovators can take their solution from the benchtop to the Biomedical Advanced Research & Development Authority (BARDA). [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bench-to-barda-start-up-series-virtual [to_ping] => [pinged] => [post_modified] => 2022-09-12 15:45:01 [post_modified_gmt] => 2022-09-12 15:45:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3908 [menu_order] => 24 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2054 [post_author] => 3 [post_date] => 2015-11-18 19:51:42 [post_date_gmt] => 2015-11-18 19:51:42 [post_content] => Traverse Biosciences has announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,187,406 entitled, "Curcumin Analogues as Zinc Chelators and Their Uses," which the company has exclusively licensed from the Research Foundation for the State University of New York (RF/SUNY). The issued patent includes claims that cover the composition of matter of the company's proprietary library of chemically-modified curcumins, including its lead drug candidate, TRB-N0224. Read more on the Traverse Biosciences website.   [post_title] => Traverse Biosciences Announces Issuance of U.S. Patent [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-announces-issuance-of-u-s-patent [to_ping] => [pinged] => [post_modified] => 2016-03-29 19:53:52 [post_modified_gmt] => 2016-03-29 19:53:52 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2054 [menu_order] => 199 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3396 [post_author] => 3 [post_date] => 2019-12-06 19:14:13 [post_date_gmt] => 2019-12-06 19:14:13 [post_content] => The Federal SBIR/STTR programs award over $3 billion in high risk R&D funding annually to qualified small businesses. The process is complex but the impact of receiving millions in non-dilutive funding is worth the effort. On January 15-16, 2020, the Center for Biotechnology will be hosting a intensive, 1.5 day workshop led by  well-known program expert and trainer, Becky Aistrup, M.B.A., Managing Partner of BBC Entrepreneurial Training & Consulting LLC. This 1.5-day session focused on the National Institutes of Health (NIH) will cover program essentials and how to compete for funding. Training is open to the public and will include:
  • Current information on the SBIR/STTR programs
  • Strategies for targeting your proposal to address the mission and requirements of the NIH
  • How to approach each section of your proposal
  • Planning your commercialization strategy
  • Writing to meet the reviewers’ expectations
Dates & Times Wed, Jan 15, 2020, 8:30 AM – 4:30 PM Thu, Jan 16, 2020 8:30 AM –12:00 PM EST Location Long Island High Technology Incubator Main Conference Room 25 Health Sciences Drive Stony Brook, NY 11794 Registration Fee: $60 Space is Limited. Pre-registration is required. REGISTER ONLINE Interested participants have the opportunity to apply for partial-sponsored follow on counseling via one-on-one proposal mentoring with SBIR/STTR experts. More info here. PLEASE NOTE: This training is mandatory for those who will be submitting applications for the One-on-One proposal counseling. [post_title] => Proposal Development Workshop: SBIR/STTR for NIH [post_excerpt] => The Federal SBIR/STTR programs award over $3 billion in high risk R&D funding annually to qualified small businesses. Learn if this opportunity is right for your technology how to develop a competitive proposal at our annual workshop. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => proposal-development-workshop-sbirsttr-for-nih [to_ping] => [pinged] => [post_modified] => 2019-12-06 19:14:13 [post_modified_gmt] => 2019-12-06 19:14:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3396 [menu_order] => 82 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 270 [max_num_pages] => 90 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Bench to BARDA Start Up Series (Virtual)

More Information

Traverse Biosciences Announces Issuance of U.S. Patent

More Information

Proposal Development Workshop: SBIR/STTR for NIH

More Information